Concourse Financial Group Securities, Inc. Outlook Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$0.22 - $0.66 $0 - $0	0 New	0 $0
Q3 2023 Oct 30, 2023	BUY	$0.2 - $1.78 $0 - $0	0 New	0 $0
Q3 2023 Oct 25, 2023	BUY	$0.2 - $1.78 $0 - $0	0 New	0 $0
Q2 2023 Aug 10, 2023	BUY	$1.02 - $1.89 $0 - $0	0 New	0 $0
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $0 - $0	0 New	0 $0
Q4 2022 Jan 30, 2023	BUY	$0.87 - $1.33 $0 - $0	0 New	0 $0
Q3 2022 Nov 15, 2022	BUY	$1.02 - $1.26 $0 - $0	0 New	0 $0
Q2 2022 Aug 09, 2022	BUY	$0.91 - $2.01 $0 - $0	0 New	0 $0
Q1 2022 May 09, 2022	SELL	$1.22 - $2.03 $1,677 - $2,791	-1,375 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$0.51 - $1.08 $701 - $1,485	1,375 New	1,375 $1,000
Q4 2019 Feb 14, 2020	BUY	$0.53 - $1.59 $0 - $0	0 New	0 $0
Q3 2019 Nov 13, 2019	BUY	$1.32 - $2.63 $0 - $0	0 New	0 $0
Q2 2019 Aug 13, 2019	BUY	$0.91 - $7.68 $0 - $0	0 New	0 $0
Q1 2019 May 15, 2019	BUY	$4.26 - $10.56 $0 - $0	0 New	0 $0

Others Institutions Holding OTLK

# of Institutions

Shares Held

31.5K

Call Options Held

Put Options Held

View Full List

About Outlook Therapeutics, Inc.

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

More about OTLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account